ALKS

SEC source: 0001127602-24-017710 · form4.xml · derivative · entry 5

Alva Emily Peterson · CIK 0001738422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,785

Underlying: Ordinary Shares · 231 shares

Expires 2032-07-07

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017710 · form4.xml · derivative · entry 4

Alva Emily Peterson · CIK 0001738422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,990

Underlying: Ordinary Shares · 313 shares

Expires 2031-06-14

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017710 · form4.xml · derivative · entry 3

Alva Emily Peterson · CIK 0001738422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,871

Underlying: Ordinary Shares · 75 shares

Expires not disclosed

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/9/2022.

F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/9/2022.

SEC source: 0001127602-24-017710 · form4.xml · derivative · entry 2

Alva Emily Peterson · CIK 0001738422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,214

Underlying: Ordinary Shares · 455 shares

Expires 2031-06-09

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: Shares subject to the stock option award vest in three equal annual installments commencing on 6/9/2022.

SEC source: 0001127602-24-017710 · form4.xml · derivative · entry 1

Alva Emily Peterson · CIK 0001738422 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,137

Underlying: Ordinary Shares · 22 shares

Expires 2031-06-09

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 8

Wilson Frank Anders · CIK 0001462948 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 119 shares

Expires not disclosed

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 7

Wilson Frank Anders · CIK 0001462948 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,986

Underlying: Ordinary Shares · 254 shares

Expires 2033-06-29

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.

SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 6

Wilson Frank Anders · CIK 0001462948 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,785

Underlying: Ordinary Shares · 231 shares

Expires 2032-07-07

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 5

Wilson Frank Anders · CIK 0001462948 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,990

Underlying: Ordinary Shares · 313 shares

Expires 2031-06-14

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 4

Wilson Frank Anders · CIK 0001462948 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,739

Underlying: Ordinary Shares · 230 shares

Expires 2030-12-02

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 3

Wilson Frank Anders · CIK 0001462948 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,079

Underlying: Ordinary Shares · 256 shares

Expires 2030-05-20

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 2

Wilson Frank Anders · CIK 0001462948 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,424

Underlying: Ordinary Shares · 224 shares

Expires 2029-12-04

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017731 · form4.xml · derivative · entry 1

Wilson Frank Anders · CIK 0001462948 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,036

Underlying: Ordinary Shares · 1,236 shares

Expires 2029-12-04

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017732 · form4.xml · derivative · entry 6

Wright Christopher I · CIK 0001838503 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 119 shares

Expires not disclosed

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

SEC source: 0001127602-24-017732 · form4.xml · derivative · entry 5

Wright Christopher I · CIK 0001838503 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,986

Underlying: Ordinary Shares · 254 shares

Expires 2033-06-29

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.

SEC source: 0001127602-24-017732 · form4.xml · derivative · entry 4

Wright Christopher I · CIK 0001838503 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,785

Underlying: Ordinary Shares · 231 shares

Expires 2032-07-07

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017732 · form4.xml · derivative · entry 3

Wright Christopher I · CIK 0001838503 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,602

Underlying: Ordinary Shares · 129 shares

Expires not disclosed

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/8/2023.

F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/8/2023.

SEC source: 0001127602-24-017732 · form4.xml · derivative · entry 2

Wright Christopher I · CIK 0001838503 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,128

Underlying: Ordinary Shares · 355 shares

Expires 2032-06-08

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: Shares subject to the stock option award vest in three equal annual installments commencing on 6/8/2023.

SEC source: 0001127602-24-017732 · form4.xml · derivative · entry 1

Wright Christopher I · CIK 0001838503 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 728

Underlying: Ordinary Shares · 14 shares

Expires 2032-06-08

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 11

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 119 shares

Expires not disclosed

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 10

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,986

Underlying: Ordinary Shares · 254 shares

Expires 2033-06-29

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 9

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,785

Underlying: Ordinary Shares · 231 shares

Expires 2032-07-07

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 8

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,990

Underlying: Ordinary Shares · 313 shares

Expires 2031-06-14

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 7

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,739

Underlying: Ordinary Shares · 230 shares

Expires 2030-12-02

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 6

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,079

Underlying: Ordinary Shares · 256 shares

Expires 2030-05-20

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 5

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,848

Underlying: Ordinary Shares · 448 shares

Expires 2029-05-22

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 4

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,850

Underlying: Ordinary Shares · 350 shares

Expires 2028-05-23

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 3

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,484

Underlying: Ordinary Shares · 284 shares

Expires 2027-05-24

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 2

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,524

Underlying: Ordinary Shares · 324 shares

Expires 2026-09-14

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017730 · form4.xml · derivative · entry 1

snyderman nancy lynn MD · CIK 0001675198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,948

Underlying: Ordinary Shares · 548 shares

Expires 2026-09-14

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017725 · form4.xml · derivative · entry 8

GAYNOR RICHARD · CIK 0001741284 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 119 shares

Expires not disclosed

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

SEC source: 0001127602-24-017725 · form4.xml · derivative · entry 7

GAYNOR RICHARD · CIK 0001741284 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,986

Underlying: Ordinary Shares · 254 shares

Expires 2033-06-29

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.

SEC source: 0001127602-24-017725 · form4.xml · derivative · entry 6

GAYNOR RICHARD · CIK 0001741284 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,785

Underlying: Ordinary Shares · 231 shares

Expires 2032-07-07

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017725 · form4.xml · derivative · entry 5

GAYNOR RICHARD · CIK 0001741284 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,990

Underlying: Ordinary Shares · 313 shares

Expires 2031-06-14

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017725 · form4.xml · derivative · entry 4

GAYNOR RICHARD · CIK 0001741284 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,739

Underlying: Ordinary Shares · 230 shares

Expires 2030-12-02

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017725 · form4.xml · derivative · entry 3

GAYNOR RICHARD · CIK 0001741284 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,079

Underlying: Ordinary Shares · 256 shares

Expires 2030-05-20

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017725 · form4.xml · derivative · entry 2

GAYNOR RICHARD · CIK 0001741284 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,424

Underlying: Ordinary Shares · 224 shares

Expires 2029-12-04

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017725 · form4.xml · derivative · entry 1

GAYNOR RICHARD · CIK 0001741284 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,036

Underlying: Ordinary Shares · 1,236 shares

Expires 2029-12-04

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017716 · form4.xml · derivative · entry 12

Cooke Shane · CIK 0001524823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,104

Underlying: Ordinary Shares · 119 shares

Expires not disclosed

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

SEC source: 0001127602-24-017716 · form4.xml · derivative · entry 11

Cooke Shane · CIK 0001524823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,986

Underlying: Ordinary Shares · 254 shares

Expires 2033-06-29

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.

SEC source: 0001127602-24-017716 · form4.xml · derivative · entry 10

Cooke Shane · CIK 0001524823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,785

Underlying: Ordinary Shares · 231 shares

Expires 2032-07-07

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017716 · form4.xml · derivative · entry 9

Cooke Shane · CIK 0001524823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,990

Underlying: Ordinary Shares · 313 shares

Expires 2031-06-14

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017716 · form4.xml · derivative · entry 8

Cooke Shane · CIK 0001524823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,739

Underlying: Ordinary Shares · 230 shares

Expires 2030-12-02

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017716 · form4.xml · derivative · entry 7

Cooke Shane · CIK 0001524823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,079

Underlying: Ordinary Shares · 256 shares

Expires 2030-05-20

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017716 · form4.xml · derivative · entry 6

Cooke Shane · CIK 0001524823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,848

Underlying: Ordinary Shares · 448 shares

Expires 2029-05-22

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017716 · form4.xml · derivative · entry 5

Cooke Shane · CIK 0001524823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,850

Underlying: Ordinary Shares · 350 shares

Expires 2028-05-23

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017716 · form4.xml · derivative · entry 4

Cooke Shane · CIK 0001524823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,520

Underlying: Ordinary Shares · 520 shares

Expires 2028-05-23

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017716 · form4.xml · derivative · entry 3

Cooke Shane · CIK 0001524823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,675

Underlying: Ordinary Shares · 425 shares

Expires 2027-02-17

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017716 · form4.xml · derivative · entry 2

Cooke Shane · CIK 0001524823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,200

Underlying: Ordinary Shares · 1,200 shares

Expires 2026-02-28

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-017716 · form4.xml · derivative · entry 1

Cooke Shane · CIK 0001524823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,227

Underlying: Ordinary Shares · 1,102 shares

Expires 2025-02-26

F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2 · derivative.exercise_date: These options are fully vested in accordance with their terms.